Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial - sprookjes - yvandenbroek - TriplyDB

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

http://www.wikidata.org/entity/Q28286240

about

Glucagon-like peptide analogues for type 2 diabetes mellitus Regulation of glucose homeostasis by GLP-1 Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies Sitagliptin/metformin fixed-dose combination in type 2 diabetes mellitus: an evidence-based review of its place in therapy Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus Emerging utility of once-weekly exenatide in patients with type 2 diabetes Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond Adverse Effects of GLP-1 Receptor Agonists GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence GLP-1, the gut-brain, and brain-periphery axes Dipeptidyl-peptidase 4 inhibition: linking metabolic control to cardiovascular protection Safety and efficacy of sitagliptin-metformin in fixed combination for the treatment of type 2 diabetes mellitus Update on the treatment of type 2 diabetes mellitus Gut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants Saxagliptin overview: special focus on safety and adverse effects Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States Consensus report: the current role of self-monitoring of blood glucose in non-insulin-treated type 2 diabetes Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.Exenatide once weekly: opportunities in the primary care setting.Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.Cardiovascular safety of the glucagon-like peptide-1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta-analysis of randomized controlled trials.Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists Utilizing Data from the Exenatide Clinical Trial Development Program.Comparison of the efficacy of sitagliptin and glimepiride dose-up in Japanese patients with type 2 diabetes poorly controlled by sitagliptin and glimepiride in combination.Once-weekly albiglutide in the management of type 2 diabetes: patient considerations.Hypoglycemia: a review of definitions used in clinical trials evaluating antihyperglycemic drugs for diabetes.Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway.Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes.Efficacy and safety of autoinjected exenatide once-weekly suspension versus sitagliptin or placebo with metformin in patients with type 2 diabetes: The DURATION-NEO-2 randomized clinical study.Exenatide once weekly treatment maintained improvements in glycemic control and weight loss over 2 years.

P2860

Q24235918-A1B10DC9-3242-4307-BE6C-48FD0F135174 Q24563430-6C19F361-CAE3-43E8-8D40-4663B91BB14B Q24568148-292FBC71-1188-4C80-A9B6-C74750CA94ED Q26739888-F4FFFF7C-9733-414A-9D93-69B4132F2E54 Q26749495-EC3004A0-52F2-4FBE-9911-E36FB9779A54 Q26752699-B29B7610-5A99-4511-80B0-7326EC31A9E7 Q26765155-61C46637-7E4C-4C0F-A083-7F11BF6B351D Q26777320-77A1CA5A-07E5-469B-A15E-6AC924CA8D4B Q26778608-7BD1C043-A951-4584-B515-BA5F4BC274B4 Q26797236-3FD4FA03-544E-47F5-A0A1-6D24AE2FABAB Q26799389-51EAAF9F-40B6-4F1B-99B6-7455C593EE5F Q26801346-779B56C9-E520-4FBB-B0B2-E647CBBC1A53 Q26858990-6925DBDC-D058-49D2-90DF-9F30D040BAB9 Q27000749-E6628CD8-C68E-45B4-AE73-3D0EA52B32F5 Q27011819-67F42213-6EB1-433C-8095-BB9972757195 Q27027877-D92A233F-7B04-4CE6-9FE6-22468673DFFF Q28073342-DECE7F86-D452-46FB-B85A-C61935C3C77B Q28081671-0BB3EB41-0915-442C-BCCB-4583001EE41B Q28088578-195E4C8E-0F17-409B-8E0E-CE3E249ECFBD Q28238585-53271B4C-6D58-46F1-B3AB-A90C6B75BF42 Q28278863-833C4466-A4D7-41DC-BDD1-B7625EE2031C Q28294225-F38DC0BD-60AE-4EA8-B5C4-D0D3F45DCFF9 Q28544980-21E5FAE4-81CD-457E-8778-E6C0146EC0E6 Q28545766-6C850D8C-E8A7-4A7F-86DD-7B96D21F4531 Q28732681-205E4E14-6238-4698-A9A0-26B92B247DA6 Q30249371-E0198958-C68F-47C2-965D-9A47E7696F06 Q30431639-7A006987-1565-483F-904B-7EB8438D75CD Q30643065-F2E533F9-D882-4BDC-9921-B52DE8CB777A Q30888375-AF0ACA12-43B1-4E0E-9D7A-6242B11732C5 Q31066859-A6F1D0A6-1A3B-4186-A101-DBF8FE497EC7 Q33608096-BED7AB9B-3687-4F00-8233-83E794BE545E Q33728226-986C6DA3-5687-41D7-A583-46FE224FA987 Q33739048-B2ECCFCA-8267-4D4E-8E33-F60E9B19363E Q33767049-39D59705-BCA2-4244-A27C-299DE244DB55 Q33785197-191DAFB7-7BDA-4B26-A3D8-9B78ECBF111D Q33786150-1905B275-A8CE-499E-9045-B7D33B1E27A2 Q33806760-60895DFF-65A3-4CF7-8518-DD0472CA0399 Q33824522-F8102463-6522-4A52-A7E4-A66D057CAD0D Q33835897-3E4CEC1B-EC6E-4A5E-A9BC-8F2BD5201477 Q33884913-B7127A0B-3F83-417B-BE47-6945856E2329

P2860

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

http://www.wikidata.org/entity/Q28286240

description

2010 nî lūn-bûn

@nan

2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Efficacy and safety of exenati ...... URATION-2): a randomised trial

@ast

Efficacy and safety of exenati ...... URATION-2): a randomised trial

@en

Efficacy and safety of exenati ...... URATION-2): a randomised trial

@nl

type

label

Efficacy and safety of exenati ...... URATION-2): a randomised trial

@ast

Efficacy and safety of exenati ...... URATION-2): a randomised trial

@en

Efficacy and safety of exenati ...... URATION-2): a randomised trial

@nl

prefLabel

Efficacy and safety of exenati ...... URATION-2): a randomised trial

@ast

Efficacy and safety of exenati ...... URATION-2): a randomised trial

@en

Efficacy and safety of exenati ...... URATION-2): a randomised trial

@nl

P1433

Q28286240-E3E1D988-C3FF-4462-98D8-33EE9E3DE4F6

P1476

Q28286240-E6E10175-D05C-4261-AB7B-2C8E189F7046

P2093

Q28286240-14F73BF0-1683-4D62-8722-1ACCBC3B8171

Q28286240-9931F02E-0C3E-46BD-B35A-0B8BCC7EBC86

Q28286240-ACD8BCFB-B78D-4CCA-B05F-C945FA52AAF9

Q28286240-B637DE2C-9FFD-4AC5-810D-62B908F0D203

Q28286240-C3676A9C-BB3D-40FB-ACDD-CA9096F31681

Q28286240-DCC1BBAE-3CE5-461C-81DF-4C918C293FFD

Q28286240-E7BF33AD-1CEF-4CA6-AD33-F180FB65A241

Q28286240-EA6CCDF0-7934-44D2-BE6E-A7386540901E

Q28286240-FA97A027-0256-47E3-96DB-9882D1B9564B

P304

Q28286240-034E2C98-BA7F-4E33-B65E-CA98FFD79D20

P31

Q28286240-6C61E939-5E4C-43F4-AB4E-262DB53E6289

P3181

Q28286240-534C63B0-C4A4-42C5-A5AC-65B4FADED7F1

P356

Q28286240-C74AEA9F-AA8B-45A5-B0F2-B77823563102

P407

Q28286240-31792E39-C9F7-475D-9D6A-12A8E2AB93B1

P433

Q28286240-53BFF7A8-6F50-4561-9458-BE5128D83785

P478

Q28286240-F5FD1873-24BB-4300-A228-76221920E031

P577

Q28286240-D56C9CFB-8C46-481C-9D51-78BF2187BB7C

P698

Q28286240-7DBABA55-7F65-4A23-B517-BBE73734296F

P921

Q28286240-0F72BE76-EBB7-4A40-A563-CA1D2729A3DF

Q28286240-2EBAE71E-F80F-4CCD-9337-71C41D39FA80

P3181

P356

S0140-6736(10)60590-9

P1433

P1476

Efficacy and safety of exenati ...... URATION-2): a randomised trial

@en

P2093

Brandon Walsh

http://www.w3.org/2001/XMLSchema#string

Carol Wysham

http://www.w3.org/2001/XMLSchema#string

Jaret Malloy

http://www.w3.org/2001/XMLSchema#string

Jim Malone

http://www.w3.org/2001/XMLSchema#string

Ken Wilhelm

http://www.w3.org/2001/XMLSchema#string

Leigh Macconell

http://www.w3.org/2001/XMLSchema#string

Lisa E Porter

http://www.w3.org/2001/XMLSchema#string

Ping Yan

http://www.w3.org/2001/XMLSchema#string

Richard M Bergenstal

http://www.w3.org/2001/XMLSchema#string

P304

431-9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1489677

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0140-6736(10)60590-9

http://www.w3.org/2001/XMLSchema#string

P407

P433

9739

http://www.w3.org/2001/XMLSchema#string

P478

376

http://www.w3.org/2001/XMLSchema#string

P577

2010-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20580422

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes